Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 5, 2007

Resverlogix Initiates Alzheimer's Research Program

  • Resverlogix initiated a research program dedicated to ApoA-I production and testing its therapeutic potential for disorders that affect cognitive function, such as Alzheimer's Disease.

    Epidemiological and mechanistic evidence indicate a link between low ApoA-I/HDL and neurodegenerative diseases. Resverlogix says it has molecules that are potent and selective in raising plasma ApoA-I/HDL by increasing ApoA-I production, which may beneficially impact AD. The Alzheimer's program will be developed by RVX Therapeutics, a wholly owned subsidiary of Resverlogix, and does not signal a change in any other processes or programs currently underway at Resverlogix.

    "There remains a great unmet need in this therapeutic area," stated Jan Johansson, senior vp of clinical affairs at Resverlogix. "The growing body of evidence illustrating the ApoA-I/HDL protective role in neurodegenerative diseases makes a compelling argument for our lead ApoA-I technology, NexVas PR."

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »